|
AU2003201573B2
(en)
*
|
2002-01-22 |
2009-02-26 |
Biomatera Inc. |
Method of drying biodegradable polymers
|
|
US20080262031A1
(en)
*
|
2005-02-04 |
2008-10-23 |
Ctg Pharma S.R.L. |
4-Aminoquinoline Derivatives as Antimalarials
|
|
PL2559690T3
(pl)
|
2005-05-10 |
2016-09-30 |
|
Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania
|
|
TWI382974B
(zh)
|
2005-12-20 |
2013-01-21 |
英塞特公司 |
作為吲哚胺２，３-二氧化酶調節劑之ｎ-羥基甲脒基雜環化物
|
|
WO2008036652A2
(en)
*
|
2006-09-19 |
2008-03-27 |
Incyte Corporation |
Amidines as modulators of indoleamine 2,3-dioxygenase
|
|
JP5319532B2
(ja)
*
|
2006-09-19 |
2013-10-16 |
インサイト・コーポレイション |
インドールアミン２，３−ジオキシゲナーゼのモジュレーターとしてのｎ−ヒドロキシアミジノヘテロサイクル
|
|
CL2007002650A1
(es)
|
2006-09-19 |
2008-02-08 |
Incyte Corp |
Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
|
|
WO2008058178A1
(en)
*
|
2006-11-08 |
2008-05-15 |
Incyte Corporation |
N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
|
|
ES2524266T3
(es)
|
2008-07-08 |
2014-12-04 |
Incyte Corporation |
1,2,5-Oxadiazoles como inhibidores de la indoleamina 2,3-dioxigenasa
|
|
JP2016501203A
(ja)
|
2012-11-20 |
2016-01-18 |
バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ |
インドールアミン２，３−ジオキシゲナーゼの阻害剤として有用な化合物
|
|
WO2015031771A2
(en)
*
|
2013-08-30 |
2015-03-05 |
Board Of Regents, The University Of Texas System |
Administration of kynurenine depleting enzymes for tumor therapy
|
|
EA201991770A1
(ru)
|
2013-11-08 |
2019-12-30 |
Инсайт Холдингс Корпорейшн |
Способ синтеза ингибитора индоламин-2,3-диоксигеназы
|
|
HUE054183T2
(hu)
|
2013-12-24 |
2021-08-30 |
Bristol Myers Squibb Co |
Triciklusos vegyület rákellenes szerekként
|
|
AU2015271709B2
(en)
|
2014-06-06 |
2020-11-26 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
|
|
EP3186371B1
(en)
|
2014-08-29 |
2024-08-14 |
Board of Regents, The University of Texas System |
Administration of kynurenine depleting enzymes for tumor therapy
|
|
TWI711630B
(zh)
|
2014-11-21 |
2020-12-01 |
美商必治妥美雅史谷比公司 |
抗ｃｄ７３抗體及其用途
|
|
AR103232A1
(es)
|
2014-12-22 |
2017-04-26 |
Bristol Myers Squibb Co |
ANTAGONISTAS DE TGFbR
|
|
MY187045A
(en)
|
2014-12-23 |
2021-08-27 |
Bristol Myers Squibb Co |
Antibodies to tigit
|
|
US10983128B2
(en)
|
2015-02-05 |
2021-04-20 |
Bristol-Myers Squibb Company |
CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
|
|
PE20171789A1
(es)
|
2015-03-02 |
2017-12-28 |
Bristol Myers Squibb Co |
Inhibidores del factor beta de crecimiento de transformacion (tgf-beta)
|
|
JP2018519245A
(ja)
|
2015-04-03 |
2018-07-19 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
癌の治療のためのインドールアミン−２，３−ジオキシゲナーゼの阻害剤およびそれらの使用方法
|
|
WO2016162505A1
(en)
|
2015-04-08 |
2016-10-13 |
F-Star Biotechnology Limited |
Her2 binding agent therapies
|
|
BR112017020952A2
(pt)
|
2015-04-13 |
2018-07-10 |
Five Prime Therapeutics Inc |
método de tratamento de câncer, composição e uso da composição
|
|
EP3294736B1
(en)
|
2015-05-11 |
2020-07-22 |
Bristol-Myers Squibb Company |
Tricyclic compounds as anticancer agents
|
|
EP3307740B1
(en)
|
2015-05-12 |
2019-12-18 |
Bristol-Myers Squibb Company |
5h-pyrido[3,2-b]indole compounds as anticancer agents
|
|
US9725449B2
(en)
|
2015-05-12 |
2017-08-08 |
Bristol-Myers Squibb Company |
Tricyclic compounds as anticancer agents
|
|
EA035412B1
(ru)
|
2015-05-29 |
2020-06-10 |
Бристол-Майерс Сквибб Компани |
Антитела к ox40 и их применение
|
|
US10479838B2
(en)
|
2015-06-29 |
2019-11-19 |
Bristol-Myers Squibb Company |
Antibodies to CD40 with enhanced agonist activity
|
|
KR20180034548A
(ko)
|
2015-07-28 |
2018-04-04 |
브리스톨-마이어스 스큅 컴퍼니 |
Tgf 베타 수용체 길항제
|
|
EP3341372A1
(en)
|
2015-08-25 |
2018-07-04 |
Bristol-Myers Squibb Company |
Tgf beta receptor antagonists
|
|
JP6936221B2
(ja)
|
2015-11-02 |
2021-09-15 |
ファイブ プライム セラピューティクス， インコーポレイテッド |
Ｃｄ８０細胞外ドメインポリペプチドと、がん治療でのそれらの使用
|
|
CA3005855A1
(en)
|
2015-11-19 |
2017-05-26 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
|
|
RU2745707C2
(ru)
|
2015-11-23 |
2021-03-30 |
Файв Прайм Терапьютикс, Инк. |
Ингибиторы fgfr2 отдельно или в комбинации с иммуностимулирующими агентами в лечении рака
|
|
JP6856648B2
(ja)
|
2015-12-15 |
2021-04-07 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
Ｃｘｃｒ４受容体アンタゴニスト
|
|
WO2017140835A1
(en)
|
2016-02-19 |
2017-08-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of obesity
|
|
US11542486B2
(en)
|
2016-03-02 |
2023-01-03 |
Board Of Regents, The University Of Texas System |
Human kynureninase enzyme variants having improved pharmacological properties
|
|
CA3016187A1
(en)
|
2016-03-04 |
2017-09-08 |
Bristol-Myers Squibb Company |
Combination therapy with anti-cd73 antibodies
|
|
JP7038064B2
(ja)
|
2016-04-18 |
2022-03-17 |
セルデックス セラピューティクス インコーポレイテッド |
ヒトｃｄ４０に結合するアゴニスト抗体およびその使用
|
|
CN109414421A
(zh)
|
2016-05-04 |
2019-03-01 |
百时美施贵宝公司 |
吲哚胺2,3-双加氧酶的抑制剂及其使用方法
|
|
EP3452029A4
(en)
|
2016-05-04 |
2019-10-30 |
Bristol-Myers Squibb Company |
INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
|
|
WO2017192813A1
(en)
|
2016-05-04 |
2017-11-09 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
JP2019516681A
(ja)
|
2016-05-04 |
2019-06-20 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
インドールアミン２，３−ジオキシゲナーゼ阻害剤およびその使用方法
|
|
KR20190003685A
(ko)
|
2016-05-04 |
2019-01-09 |
브리스톨-마이어스 스큅 컴퍼니 |
인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법
|
|
SG11201900026TA
(en)
|
2016-07-14 |
2019-01-30 |
Bristol Myers Squibb Co |
Antibodies against tim3 and uses thereof
|
|
WO2018017633A1
(en)
|
2016-07-21 |
2018-01-25 |
Bristol-Myers Squibb Company |
TGF Beta RECEPTOR ANTAGONISTS
|
|
CN109843322A
(zh)
|
2016-08-26 |
2019-06-04 |
百时美施贵宝公司 |
吲哚胺2,3-双加氧酶的抑制剂及其使用方法
|
|
UY37466A
(es)
|
2016-11-03 |
2018-01-31 |
Phenex Discovery Verwaltungs Gmbh |
N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa
|
|
EP3842442B1
(en)
|
2016-12-22 |
2023-11-01 |
Precision Pharmaceuticals, Inc. |
Compositions and methods for inhibiting arginase activity
|
|
US10961239B2
(en)
|
2017-01-05 |
2021-03-30 |
Bristol-Myers Squibb Company |
TGF beta receptor antagonists
|
|
JP2020506895A
(ja)
|
2017-01-17 |
2020-03-05 |
ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System |
インドールアミン２，３−ジオキシゲナーゼおよび／またはトリプトファンジオキシゲナーゼの阻害剤として有用な化合物
|
|
US11034661B2
(en)
*
|
2017-03-29 |
2021-06-15 |
Merck Sharp & Dohme Corp. |
Substituted N′-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase IDO inhibitors
|
|
JP2020512357A
(ja)
|
2017-03-31 |
2020-04-23 |
ファイブ プライム セラピューティクス， インコーポレイテッド |
抗ｇｉｔｒ抗体を使用した癌の併用療法
|
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
|
FI3612030T3
(fi)
|
2017-04-21 |
2026-03-20 |
Pahr Therapeutics Inc |
Ahr:n indoliestäjiä ja niiden käyttötapoja
|
|
AU2018258661A1
(en)
|
2017-04-28 |
2019-10-17 |
Five Prime Therapeutics, Inc. |
Methods of treatment with CD80 extracellular domain polypeptides
|
|
US11066392B2
(en)
|
2017-05-12 |
2021-07-20 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
KR101965348B1
(ko)
*
|
2017-06-26 |
2019-04-03 |
한국화학연구원 |
N'-히드록시인다졸카르복시이미다미드 유도체 화합물, 이의 광학이성질체, 또는 이의 약학적으로 허용가능한 염, 및, 이를 유효성분으로 포함하는 항암용 조성물
|
|
EP3645519A1
(en)
*
|
2017-06-28 |
2020-05-06 |
GlaxoSmithKline Intellectual Property Development Limited |
Modulators of indoleamine 2,3-dioxygenase
|
|
BR112019026910A2
(pt)
*
|
2017-06-28 |
2020-06-30 |
Glaxosmithkline Intellectual Property Development Limited |
composto, composição farmacêutica, forma de dosagem unitária, método para tratar uma doença ou condição, e, uso de um composto ou sal.
|
|
EA202090119A1
(ru)
|
2017-06-30 |
2020-04-21 |
Бристол-Маерс Сквибб Компани |
Аморфные и кристаллические формы ido-ингибиторов
|
|
ES2932354T3
(es)
|
2017-07-28 |
2023-01-18 |
Bristol Myers Squibb Co |
Dinucleótidos cíclicos como agentes anticáncer
|
|
SG11202001310SA
(en)
|
2017-08-17 |
2020-03-30 |
Ikena Oncology Inc |
Ahr inhibitors and uses thereof
|
|
WO2019046498A1
(en)
|
2017-08-31 |
2019-03-07 |
Bristol-Myers Squibb Company |
CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
|
|
ES2904317T3
(es)
|
2017-08-31 |
2022-04-04 |
Bristol Myers Squibb Co |
Dinucleótidos cíclicos como agentes anticancerosos
|
|
EP3676277A1
(en)
|
2017-08-31 |
2020-07-08 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
|
WO2019043103A1
(en)
*
|
2017-09-01 |
2019-03-07 |
Netherlands Translational Research Center B.V. |
3-HYDROXY-IMIDAZOLIDIN-4-ONE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE
|
|
WO2019074822A1
(en)
|
2017-10-09 |
2019-04-18 |
Bristol-Myers Squibb Company |
INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
|
|
US11203592B2
(en)
|
2017-10-09 |
2021-12-21 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
WO2019074887A1
(en)
|
2017-10-10 |
2019-04-18 |
Bristol-Myers Squibb Company |
CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
|
|
EP3694552A1
(en)
|
2017-10-10 |
2020-08-19 |
Tilos Therapeutics, Inc. |
Anti-lap antibodies and uses thereof
|
|
EP3697801B1
(en)
|
2017-10-16 |
2024-11-20 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
|
CN111542544A
(zh)
|
2017-11-01 |
2020-08-14 |
百时美施贵宝公司 |
用于治疗癌症的免疫刺激性激动性抗体
|
|
WO2019090198A1
(en)
|
2017-11-06 |
2019-05-09 |
Bristol-Myers Squibb Company |
Isofuranone compounds useful as hpk1 inhibitors
|
|
WO2019115586A1
(en)
|
2017-12-12 |
2019-06-20 |
Phenex Discovery Verwaltungs-GmbH |
Oxalamides as modulators of indoleamine 2,3-dioxygenase
|
|
JP7284759B2
(ja)
|
2017-12-27 |
2023-05-31 |
ブリストル－マイヤーズ スクイブ カンパニー |
抗ｃｄ４０抗体およびその使用
|
|
US11447449B2
(en)
|
2018-01-05 |
2022-09-20 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
JP7358361B2
(ja)
|
2018-01-12 |
2023-10-10 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｔｉｍ３に対する抗体およびその使用
|
|
US10519187B2
(en)
|
2018-02-13 |
2019-12-31 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
|
US11945834B2
(en)
|
2018-03-08 |
2024-04-02 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
|
MX2020009786A
(es)
|
2018-03-21 |
2020-10-12 |
Five Prime Therapeutics Inc |
Anticuerpos de union a supresor de la activacion de celulas t que contiene el dominio variable de inmunoglobulina (vista) a ph acido.
|
|
CA3093407A1
(en)
|
2018-03-23 |
2019-09-26 |
Bristol-Myers Squibb Company |
Antibodies against mica and/or micb and uses thereof
|
|
US20210122757A1
(en)
|
2018-03-29 |
2021-04-29 |
Phenex Discovery Verwaltungs-GmbH |
Spirocyclic compounds as modulators of indoleamine 2,3-dioxygenase
|
|
JP2021521182A
(ja)
|
2018-04-12 |
2021-08-26 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
Ｃｄ７３アンタゴニストとｐｄ−１／ｐｄ−ｌ１軸アンタゴニストの組み合わせ治療
|
|
BR112020020772A2
(pt)
|
2018-04-16 |
2021-02-02 |
Board Of Regents, The University Of Texas System |
enzimas quinureninase humana e usos das mesmas
|
|
AU2019255196A1
(en)
|
2018-04-16 |
2020-11-12 |
Arrys Therapeutics, Inc. |
EP4 inhibitors and use thereof
|
|
WO2019206800A1
(en)
|
2018-04-24 |
2019-10-31 |
Phenex Discovery Verwaltungs-GmbH |
Spirocyclic compounds as modulators of indoleamine 2,3-dioxygenase
|
|
US12037323B2
(en)
|
2018-05-03 |
2024-07-16 |
Bristol-Myers Squibb Company |
Uracil derivatives as Mer-AXL inhibitors
|
|
US11866430B2
(en)
|
2018-06-27 |
2024-01-09 |
Bristol-Myers Squibb Company |
Naphthyridinone compounds useful as T cell activators
|
|
RS64641B1
(sr)
|
2018-06-27 |
2023-10-31 |
Bristol Myers Squibb Co |
Supstituisana jedinjenja naftiridinona korisna kao aktivatori t ćelija
|
|
TWI819024B
(zh)
|
2018-07-09 |
2023-10-21 |
美商戊瑞治療有限公司 |
結合至ｉｌｔ４的抗體
|
|
WO2020014327A2
(en)
|
2018-07-11 |
2020-01-16 |
Five Prime Therapeutics, Inc. |
Antibodies binding to vista at acidic ph
|
|
WO2020018670A1
(en)
|
2018-07-17 |
2020-01-23 |
Board Of Regents, The University Of Texas System |
Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
|
|
WO2020023356A1
(en)
|
2018-07-23 |
2020-01-30 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
US12059420B2
(en)
|
2018-07-23 |
2024-08-13 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
US11253525B2
(en)
|
2018-08-29 |
2022-02-22 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
US10959986B2
(en)
|
2018-08-29 |
2021-03-30 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
US11130802B2
(en)
|
2018-10-10 |
2021-09-28 |
Tilos Therapeutics, Inc. |
Anti-lap antibody variants
|
|
BR112021009111A2
(pt)
|
2018-11-16 |
2021-08-24 |
Bristol-Myers Squibb Company |
Anticorpos anti-nkg2a e usos dos mesmos
|
|
WO2020231766A1
(en)
|
2019-05-13 |
2020-11-19 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
|
WO2020231713A1
(en)
|
2019-05-13 |
2020-11-19 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
|
US20220306630A1
(en)
|
2019-08-06 |
2022-09-29 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
|
AR119821A1
(es)
|
2019-08-28 |
2022-01-12 |
Bristol Myers Squibb Co |
Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
|
|
MX2022003204A
(es)
|
2019-09-19 |
2022-04-18 |
Bristol Myers Squibb Co |
Anticuerpos de union al supresor de activacion de linfocitos t que contiene inmunoglobulina con dominio v (vista) a ph acido.
|
|
KR20220103753A
(ko)
|
2019-11-19 |
2022-07-22 |
브리스톨-마이어스 스큅 컴퍼니 |
헬리오스 단백질의 억제제로서 유용한 화합물
|
|
MX2022006308A
(es)
|
2019-11-26 |
2022-06-22 |
Ikena Oncology Inc |
Derivados de carbazol polimorfos y usos de los mismos.
|
|
WO2021108288A1
(en)
|
2019-11-26 |
2021-06-03 |
Bristol-Myers Squibb Company |
Salts/cocrystals of (r)-n-(4-chlorophenyl)-2-((1s,4s)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide
|
|
ES3013568T3
(en)
|
2019-12-23 |
2025-04-14 |
Bristol Myers Squibb Co |
Substituted heteroaryl compounds useful as t cell activators
|
|
AR120823A1
(es)
|
2019-12-23 |
2022-03-23 |
Bristol Myers Squibb Co |
Compuestos bicíclicos sustituidos útiles como activadores de células t
|
|
WO2021133751A1
(en)
|
2019-12-23 |
2021-07-01 |
Bristol-Myers Squibb Company |
Substituted quinazolinyl compounds useful as t cell activators
|
|
BR112022012220A2
(pt)
|
2019-12-23 |
2022-09-13 |
Bristol Myers Squibb Co |
Compostos de piperazina quinolinonil substituída úteis como ativadores de célula t
|
|
MX2022007130A
(es)
|
2019-12-23 |
2022-07-11 |
Bristol Myers Squibb Co |
Derivados de piperazina sustituidos utiles como activadores de celulas t.
|
|
CA3166898A1
(en)
|
2020-01-06 |
2021-07-15 |
Hifibio (Hk) Limited |
Anti-tnfr2 antibody and uses thereof
|
|
WO2021139682A1
(en)
|
2020-01-07 |
2021-07-15 |
Hifibio (Hk) Limited |
Anti-galectin-9 antibody and uses thereof
|
|
TW202140473A
(zh)
|
2020-01-15 |
2021-11-01 |
美商纜圖藥品公司 |
Map4k1抑制劑
|
|
EP4118118A1
(en)
|
2020-03-09 |
2023-01-18 |
Bristol-Myers Squibb Company |
Antibodies to cd40 with enhanced agonist activity
|
|
TW202140441A
(zh)
|
2020-03-23 |
2021-11-01 |
美商必治妥美雅史谷比公司 |
經取代之側氧基異吲哚啉化合物
|
|
US20230272056A1
(en)
|
2020-04-09 |
2023-08-31 |
Merck Sharp & Dohme Llc |
Affinity matured anti-lap antibodies and uses thereof
|
|
WO2021231732A1
(en)
|
2020-05-15 |
2021-11-18 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
|
WO2021258010A1
(en)
|
2020-06-19 |
2021-12-23 |
Gossamer Bio Services, Inc. |
Oxime compounds useful as t cell activators
|
|
US20230303695A1
(en)
|
2020-08-10 |
2023-09-28 |
Tengfei XIAO |
Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8
|
|
WO2022081718A1
(en)
|
2020-10-14 |
2022-04-21 |
Five Prime Therapeutics, Inc. |
Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
|
|
CA3202330A1
(en)
|
2020-12-16 |
2022-06-23 |
Anthony Casarez |
Compounds useful as t cell activators
|
|
WO2022169921A1
(en)
|
2021-02-04 |
2022-08-11 |
Bristol-Myers Squibb Company |
Benzofuran compounds as sting agonists
|
|
CA3210553A1
(en)
|
2021-02-12 |
2022-08-18 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydroazepine derivatives for the treatment of cancer
|
|
EP4305041A1
(en)
|
2021-03-08 |
2024-01-17 |
Blueprint Medicines Corporation |
Map4k1 inhibitors
|
|
WO2022197641A1
(en)
|
2021-03-15 |
2022-09-22 |
Rapt Therapeutics, Inc. |
1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases
|
|
EP4314068A1
(en)
|
2021-04-02 |
2024-02-07 |
The Regents Of The University Of California |
Antibodies against cleaved cdcp1 and uses thereof
|
|
JP2024515545A
(ja)
|
2021-04-05 |
2024-04-10 |
ブリストル－マイヤーズ スクイブ カンパニー |
がん治療のためのピリジニル置換オキソイソインドリン化合物
|
|
PT4320112T
(pt)
|
2021-04-06 |
2025-07-07 |
Bristol Myers Squibb Co |
Compostos de oxoisoindolina substituídos por piridinilo
|
|
MX2024000751A
(es)
|
2021-07-14 |
2024-03-25 |
Blueprint Medicines Corp |
Compuestos heterociclicos como inhibidores de map4k1.
|
|
CN117940406A
(zh)
|
2021-07-15 |
2024-04-26 |
缆图药品公司 |
Map4k1抑制剂
|
|
WO2023122772A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Oxime derivatives useful as t cell activators
|
|
WO2023122777A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Oxime derivatives useful as t cell activators
|
|
WO2023122778A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Pyridazinone derivatives useful as t cell activators
|
|
JP2025503312A
(ja)
|
2022-02-01 |
2025-01-30 |
アルビナス・オペレーションズ・インコーポレイテッド |
Ｄｇｋ標的化化合物およびその使用
|
|
EP4568950A1
(en)
|
2022-08-08 |
2025-06-18 |
Bristol-Myers Squibb Company |
Substituted tetrazolyl compounds useful as t cell activators
|
|
KR20250046310A
(ko)
|
2022-08-09 |
2025-04-02 |
브리스톨-마이어스 스큅 컴퍼니 |
T 세포 활성화제로서 유용한 3급 아민 치환된 비시클릭 화합물
|
|
JP2025526727A
(ja)
|
2022-08-11 |
2025-08-15 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
二環式テトラヒドロチアゼピン誘導体
|
|
TW202417001A
(zh)
|
2022-08-11 |
2024-05-01 |
瑞士商赫孚孟拉羅股份公司 |
雙環四氫吖呯衍生物
|
|
JP2025526681A
(ja)
|
2022-08-11 |
2025-08-15 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
二環式テトラヒドロチアゼピン誘導体
|
|
EP4568746B1
(en)
|
2022-08-11 |
2026-04-29 |
F. Hoffmann-La Roche AG |
Bicyclic tetrahydrothiazepine derivatives
|
|
WO2024137865A1
(en)
|
2022-12-22 |
2024-06-27 |
Gossamer Bio Services, Inc. |
Compounds useful as t cell activators
|
|
KR20250019700A
(ko)
|
2023-05-08 |
2025-02-10 |
브리스톨-마이어스 스큅 컴퍼니 |
치환된 페닐 옥사졸론 화합물
|
|
WO2024233900A1
(en)
|
2023-05-10 |
2024-11-14 |
Blueprint Medicines Corporation |
Gsk3a inhibitors and methods of use thereof
|
|
EP4719607A1
(en)
|
2023-05-31 |
2026-04-08 |
Bristol-Myers Squibb Company |
Substituted oxazolone compound for decreasing levels of ikzf1-4 proteins
|
|
AU2024285766A1
(en)
|
2023-06-07 |
2026-01-08 |
Bristol-Myers Squibb Company |
Spirocyclic substituted oxoisoindolinyl piperidine-2,6-dione compound
|
|
AU2024314878A1
(en)
|
2023-06-23 |
2026-01-22 |
Bristol-Myers Squibb Company |
Substituted oxoisoindolinyl piperidine-2,6-dione compound as anticancer agent
|
|
WO2025030002A2
(en)
|
2023-08-02 |
2025-02-06 |
Arvinas Operations, Inc. |
Dgk targeting compounds and uses thereof
|
|
KR102834908B1
(ko)
|
2023-09-02 |
2025-07-16 |
브리스톨-마이어스 스큅 컴퍼니 |
치환된 페닐 옥소옥사졸릴 피페리딘 디온 화합물
|
|
WO2025064197A1
(en)
|
2023-09-02 |
2025-03-27 |
Bristol-Myers Squibb Company |
Substituted azetidinyl oxoisoindolinyl piperidine-2,6-dione compounds
|
|
WO2025059245A1
(en)
|
2023-09-13 |
2025-03-20 |
Bristol-Myers Squibb Company |
Substituted oxoisoindolinyl piperidine-2,6-dione compounds
|
|
US20250145590A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025096487A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025096490A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025096488A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025096505A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025096489A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025096494A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025226767A1
(en)
|
2024-04-24 |
2025-10-30 |
Bristol-Myers Squibb Company |
Substituted 3-(5-(6-aminopyridin-2-yl)-4-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds for use in the treatment of cancer
|
|
WO2026035787A1
(en)
|
2024-08-07 |
2026-02-12 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) macrocyles
|
|
WO2026080794A1
(en)
|
2024-10-11 |
2026-04-16 |
Bristol-Myers Squibb Company |
Chemical compounds useful for degrading proteins
|
|
WO2026090348A1
(en)
|
2024-10-24 |
2026-04-30 |
Mirati Therapeutics, Inc. |
The use of son of sevenless (sos) inhibitor compounds such as 7-substituted benzofurans to treat cancer
|